drugset
drugset / Trial / NCT04095221

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

NCT04095221 ↗

Phase 1/2 Completed 21 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test whether the study drug prexasertib is a safe and effective treatment for people with DSRCT or RMS when given in combination with the standard drugs irinotecan and temozolomide. The study will test different doses of prexasertib in combination with irinotecan and temozolomide to find the highest dose of prexasertib that causes few or mild side effects in participants.

Timeline

Start
2019-09-17
Primary completion
2025-02-18
Completion
2025-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Prexasertib Small molecule 60 mg/m2 —
Subject Prexasertib Small molecule 80 mg/m2 —
Subject Prexasertib Small molecule 105 mg/m2 —
Subject Prexasertib Small molecule 150 mg/m2 —
Background Irinotecan Small molecule 15 mg/m2 Intravenous

Indications

desmoplastic small round cell tumor rhabdomyosarcoma